Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group

Pas, Tommaso De; Bodei, Lisa; Pelosi, Giuseppe; Braud, Filippo de; Villa, Giulia; Capanna, Rodolfo; Paganelli, Giovanni

doi:10.1038/sj.bjc.6600823

Cited by 11 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are data suggesting that some tumors have somatostatin receptor subtype 2 and may respond to treatment with a yttrium-90-radiolabeled somatostatin analog. 29 …”

Section: Resultsmentioning

confidence: 97%

Aggressive Fibromatosis

Mendenhall¹,

Zlotecki²,

Morris³

et al. 2005

American Journal of Clinical Oncology

View full text Add to dashboard Cite

The purpose of this article is to review the pertinent literature and to define the optimal treatment of patients with aggressive fibromatosis. Data indicate the likelihood of local recurrence after surgery is high, particularly if margins are positive. Moderate-dose radiotherapy alone for gross disease or after a microscopically incomplete resection yields local control rates of approximately 75% to 80%. Treatment with pharmacologic agents results in objective response rates of approximately 40% to 50%; duration of response is variable. Thus, the optimal management for aggressive fibromatosis depends on tumor location and extent. Surgery is indicated if the lesion appears to be completely resectable with acceptable function and cosmesis. Radiotherapy is indicated for patients with unresectable tumors; those with positive margins after resection should be considered for adjuvant radiotherapy depending on the location and extent of the tumor. Pharmacologic treatment should be considered for patients with progressive disease after unsuccessful local-regional therapy.

show abstract

“…There are data suggesting that some tumors have somatostatin receptor subtype 2 and may respond to treatment with a yttrium-90-radiolabeled somatostatin analog. 29 …”

Section: Resultsmentioning

confidence: 97%

Aggressive Fibromatosis

Mendenhall¹,

Zlotecki²,

Morris³

et al. 2005

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…In our present series, nine of 80 samples were positive for somatostatin. The benefit of treatment with peptide receptor radiotherapy using a somatostatin analogue, as proposed by De Pas and colleagues, 25 remains unclear.…”

Section: Discussionmentioning

confidence: 99%

Immunohistochemical analysis of desmoid tumours

Leithner

Gapp²,

Radl³

et al. 2005

J Clin Pathol

View full text Add to dashboard Cite

Background/Aims: Although the standard treatment for desmoid tumours is complete surgical resection with wide margins, the optimal adjuvant treatment for recurrent or inoperable disease is unclear, often being based on sporadic immunohistochemical reports with a low number of cases. Therefore, a large immunohistochemical study was performed, to provide a theoretical basis for adjuvant treatment regimens. Methods: One hundred and sixteen tissue samples from 80 patients (49 female, 31 male; mean age, 34 years; range, 0-83) with desmoid tumours (46 extra-abdominal, 21 abdominal, 13 intra-abdominal) were tested for oestrogen receptors a and b, progesterone and androgen receptors, and somatostatin, in addition to HER2, cathepsin D, Ki-67, and c-KIT by immunohistochemistry. Results: All samples were negative for oestrogen receptor a, HER2, and the progesterone receptor. Positive staining for the androgen receptor was found in six extra-abdominal cases. Staining for oestrogen receptor b was positive in four extra-abdominal, two abdominal, and one intra-abdominal case. Staining for somatostatin was positive in six extra-abdominal, two abdominal, and one intra-abdominal case, and staining for cathepsin D was positive in all cases. Positive staining for Ki-67 was found in 14 extraabdominal, three abdominal, and three intra-abdominal cases. C-KIT was detectable in one abdominal case only. Conclusions: The data from this immunohistochemical study show that the published effects of antioestrogens and imatinib mesylate in the treatment of aggressive fibromatoses may not be attributable to oestrogen receptor a or c-KIT expression.

show abstract

“…Two other studies analyzed somatostatin receptor expression in desmoid-type fibromatosis. De Pas et al [46] found positive reactions in two out of ten patients. Leithner et al [19] described nine positive samples out of 80.…”

Section: Somatostatinmentioning

confidence: 97%

“…Leithner et al [19] described nine positive samples out of 80. It is unclear whether therapy of desmoid tumors with peptide receptor radiotherapy using a somatostatin analogue as proposed by De Pas et al [46] is advantagsous.…”

Section: Somatostatinmentioning

confidence: 99%

Is Wide Resection Obsolete for Desmoid Tumors in Children and Adolescents? Evaluation of Histological Margins, Immunohistochemical Markers, and Review of Literature

Woltsche

Gilg

Fraissler

et al. 2014

Pediatric Hematology and Oncology

View full text Add to dashboard Cite

Desmoid fibromatosis is a benign fibroblastic neoplasm with high recurrence rates predominantly observed in pediatric and adolescent patients. The use of wide resection margins has been discussed controversially in literature. In addition, data on non-surgical treatment is limited as phase III studies are still missing. Nineteen patients under the age of 18 years were identified. Tumor location, surgical treatment for primary or recurrent tumors, resection margins, medical neo-/adjuvant treatment, time to recurrence as well as immunohistochemical markers (estrogen receptor, ER α and β, progesterone and androgen receptors, somatostatin, Ki-67, c-kit, platelet-derived growth factor receptors, PDGFRs, α and β, β-catenin) were evaluated. The mean age at diagnosis was 6.6 years, with a mean follow-up of 114 months. Recurrences were detected in four out of nineteen patients. Surprisingly, the recurrence rate was not influenced by type of resection used (R0, R1/2). All samples were tested negative for ER α, somatostatin, and progesterone receptor. In contrast, a majority of tumors showed positive results for PDGFR α and β and β-catenin. No correlation between positive immunohistochemical markers and tumor recurrences was detectable. In conclusion, recurrence rates are not depending on resection type and immunohistochemical markers seem to behave differently in children and adolescents in contrast to adult patients.

show abstract

Peptide receptor radiotherapy: a new option for the management of aggressive fibromatosis on behalf of the Italian Sarcoma Group

Cited by 11 publications

References 13 publications

Aggressive Fibromatosis

Aggressive Fibromatosis

Immunohistochemical analysis of desmoid tumours

Is Wide Resection Obsolete for Desmoid Tumors in Children and Adolescents? Evaluation of Histological Margins, Immunohistochemical Markers, and Review of Literature

Contact Info

Product

Resources

About